Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

Biosimilars Rheumatology Roundup for February 2024—Podcast Edition

March 3rd 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.

Patterns of Treatment With Biologics in Patients With Crohn Disease

March 2nd 2024

By Deana Ferreri, PhD

Article

A retrospective study analyzing 3 years of treatment patterns for patients with Crohn disease on biologics found that while more patients received infliximab, adalimumab, and vedolizumab initially, ustekinumab showed the highest persistence and lowest dose escalation rate, indicating potentially better clinical response compared to other biologics.

Quiz: The Global Biosimilar Landscape

March 1st 2024

By The Center for Biosimilars Staff

Article

Explore the dynamic world of global biosimilar markets and policies! What do you know about the international biosimilar industry?

The Top 5 Biosimilar Articles for the Week of February 26

March 1st 2024

By Cameron Santoro

Video

Here are the top 5 articles for the week of February 26, 2024.

Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More

February 29th 2024

By Skylar Jeremias

Article

In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.

Biosimilars Rheumatology Roundup: February 2024

February 29th 2024

By Skylar Jeremias

Article

During February, the global biosimilar industry saw some progress for rheumatology biosimilars, including the 10th approval for an adalimumab biosimilar in the US, as well as unique results from a clinical trial investigating the impact of adalimumab biosimilars on COVID-19 antibodies.

Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings

February 28th 2024

By Skylar Jeremias

Article

A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.

Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates

February 27th 2024

By Skylar Jeremias

Article

Samsung Bioepis provided multiple updates on its biosimilar projects, including a new partnership for its aflibercept biosimilar candidate as well as regulatory news in the European Union and Republic of Korea.

The Underlying Economics of Unbranded Biologics

February 26th 2024

By Dinakaran Balasubramanian

Article

Unbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.

Patent Shift Predictions, Legal Landscapes of Biosimilars With Ha Kung Wong

February 25th 2024

By Cameron Santoro

Video

Ha Kung Wong, JD, examines proposed patent law changes that could significantly impact the biosimilars sector, including limitations on asserted patents, elimination of interchangeability requirements, and heightened oversight of pharmacy benefit managers.